A landmark trial has confirmed real-time continuous glucose monitoring (CGM) improves blood sugar control in type 2 diabetes, while new wearable sensors promise broader, continuous biomarker tracking.

Dexcom’s new CEO is eyeing growth in the international market as a key strategy for 2026, fresh off the back of the company reporting strong full year 2025 (FY25) revenues. Speaking at the ongoing J.P ...

Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s. The company ...